Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127696911 | 12769691 | 1 | I | 20160919 | 20160922 | 20160922 | EXP | RO-ROCHE-1832333 | ROCHE | SUCEVEANU A, MAZILU L, ARAMA V, SUCEVEANU A, PAREPA I, CENUSA A, CATINEAN A, CRACIUN L AND VOINEA F. MAJOR DRIVERS INFLUENCING ADHERENCE AND QUALITY OF LIFE DURING ANTIVIRAL TRIPLE THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C . ARS MEDICA TOMITANA 2016 MAY 01;22 (2):83-91. | 0.00 | Y | 0.00000 | 20160922 | OT | RO | RO |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127696911 | 12769691 | 1 | PS | RIBAVIRIN. | RIBAVIRIN | 1 | Unknown | U | 21511 | ||||||||||
| 127696911 | 12769691 | 2 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | U | 21511 | |||||||||||
| 127696911 | 12769691 | 3 | SS | Peg-Interferon Alfa 2a | PEGINTERFERON ALFA-2A | 1 | Unknown | U | 103964 | ||||||||||
| 127696911 | 12769691 | 4 | SS | Peg-Interferon Alfa 2a | PEGINTERFERON ALFA-2A | 1 | U | 103964 | |||||||||||
| 127696911 | 12769691 | 5 | SS | PEGINTERFERON ALFA-2B | PEGINTERFERON ALFA-2B | 1 | Unknown | U | 0 | ||||||||||
| 127696911 | 12769691 | 6 | SS | PEGINTERFERON ALFA-2B | PEGINTERFERON ALFA-2B | 1 | U | 0 | |||||||||||
| 127696911 | 12769691 | 7 | I | TELAPREVIR | TELAPREVIR | 1 | Unknown | U | 0 | ||||||||||
| 127696911 | 12769691 | 8 | I | TELAPREVIR | TELAPREVIR | 1 | U | 0 | |||||||||||
| 127696911 | 12769691 | 9 | SS | BOCEPREVIR | BOCEPREVIR | 1 | Unknown | U | 0 | ||||||||||
| 127696911 | 12769691 | 10 | SS | BOCEPREVIR | BOCEPREVIR | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127696911 | 12769691 | 1 | Chronic hepatitis C |
| 127696911 | 12769691 | 2 | Hepatic cirrhosis |
| 127696911 | 12769691 | 3 | Chronic hepatitis C |
| 127696911 | 12769691 | 4 | Hepatic cirrhosis |
| 127696911 | 12769691 | 5 | Chronic hepatitis C |
| 127696911 | 12769691 | 6 | Hepatic cirrhosis |
| 127696911 | 12769691 | 7 | Chronic hepatitis C |
| 127696911 | 12769691 | 8 | Hepatic cirrhosis |
| 127696911 | 12769691 | 9 | Chronic hepatitis C |
| 127696911 | 12769691 | 10 | Hepatic cirrhosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127696911 | 12769691 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127696911 | 12769691 | Anaemia | |
| 127696911 | 12769691 | Chills | |
| 127696911 | 12769691 | Diarrhoea | |
| 127696911 | 12769691 | Drug interaction | |
| 127696911 | 12769691 | Dysgeusia | |
| 127696911 | 12769691 | Fatigue | |
| 127696911 | 12769691 | Gastrointestinal disorder | |
| 127696911 | 12769691 | General physical health deterioration | |
| 127696911 | 12769691 | Influenza like illness | |
| 127696911 | 12769691 | Insomnia | |
| 127696911 | 12769691 | Irritability | |
| 127696911 | 12769691 | Leukopenia | |
| 127696911 | 12769691 | Nausea | |
| 127696911 | 12769691 | Neutropenia | |
| 127696911 | 12769691 | Pruritus | |
| 127696911 | 12769691 | Rash | |
| 127696911 | 12769691 | Thrombocytopenia | |
| 127696911 | 12769691 | Vomiting | |
| 127696911 | 12769691 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |